Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Small Cell Lung Carcinoma 52Neoplasms 8Melanoma 8Carcinoma, Renal Cell 7Squamous Cell Carcinoma of Head and Neck 6Mesothelioma, Malignant 6Mesothelioma 6Colorectal Neoplasms 6Carcinoma 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Respiratory Tract Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms by Site 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Diseases 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Esophageal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Bronchogenic 3Bronchial Neoplasms 3Adenocarcinoma of Lung 3

Interventions

durvalumab 2tremelimumab 1ceralasertib 1aflutinib 1Radiotherapy 1Pemetrexed 1Gemcitabine 1Cisplatin 1Carboplatin 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non Small Cell Lung Cancer NSCLC × durvalumab × Thoracic × Clear all
NCT03164616 2026-03-13

POSEIDON

AstraZeneca

Phase 3 Active not recruiting
1,186 enrolled 26 charts 1 FDA
Thoracic

Non Small Cell Lung Cancer NSCLC

NCT06680050 2025-12-18

AUSTRAL

Mario Negri Institute for Pharmacological Research

Phase 2 Recruiting
21 enrolled
Thoracic

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡